Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome

BACKGROUND: Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease. The disease is relatively common among people with decompensated cirrhosis. Terlipressin is a drug that increases the blood flow to the kidneys by constricting blood vessels. The previous...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cochrane Database Syst Rev
Egile Nagusiak: Allegretti, Andrew S, Israelsen, Mads, Krag, Aleksander, Jovani, Manol, Goldin, Alison H, Schulman, Allison R, Winter, Rachel W, Gluud, Lise Lotte
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2017
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6481608/
https://ncbi.nlm.nih.gov/pubmed/29943803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD005162.pub4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak